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The injection of endothelial progenitor cells and mononuclear cells derived from bone marrow at the
ischemic region of peripheral artery disease patients is reported to be effective for therapeutic angio-
genesis; however, these cell therapies require large amounts of bone marrow to obtain sufﬁcient
numbers of cells. To solve this problem, we attempted to culture bone-marrow-derived mesenchymal
stem cells (BM-MSC), which are supposed to secrete several cytokines that promote angiogenesis. We
also focused on using platelet-rich plasma (PRP) as a supplement for cell culture instead of fetal bovine
serum. Human BM-MSC obtained from healthy volunteers expanded rapidly when cultured with 10% PRP
prepared from their own blood. FACS analysis revealed that these cultured human MSC were homoge-
neous populations, and chromosomal analysis showed a normal karyotype. Moreover, the angiogenetic
effect was apparent two weeks after human BM-MSC were injected into the ischemic muscle in SCID
mice. Tumor formation was not detected three months after injection into SCID mice either subcuta-
neously or intramuscularly. To simulate clinical settings, canine BM-MSC were grown with canine PRP
and injected into their ischemic muscles. We conﬁrmed that donor cells existed in situ two and six weeks
after operation without any side effects. These results suggest that cultured human BM-MSC can be a
promising cell source for therapeutic angiogenesis.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
The number of diabetic patients is increasing rapidly, not only in
Japan, but also throughout the world. Many of them suffer from
complications such as micro- and macro-angiopathy, followed by
intractable foot ulcers and diabetic gangrene. Many patients also
suffer from claudication due to ischemia caused by arteriosclerosis
of the femoral artery. Several studies have reported that the in-
jection of endothelial progenitor cells or mononuclear cells derived
from bone marrow at ischemic region of peripheral artery disease-ku, Tokyo, 162-8655, Japan.
).
se Society for Regenerative
ative Medicine. Production and hopatients was effective in inducing therapeutic angiogenesis [1e3].
However, one problem has been how to obtain the large number of
cells needed for injection. In one example, bone-marrow-derived
mononuclear cells were prepared from 400 to 800 ml of bone
marrow; this required frequently repeated bone marrow aspiration
under general anesthesia. It is clear that this approach is not always
applicable to all patients. To solve this dilemma, we focused on
bone-marrow-derived mesenchymal cells (BM-MSC), because they
have been shown to secrete several cytokines, including angiogenic
factors and immunomodulatory molecules that promote angio-
genesis and wound healing [4]. Moreover, they have been reported
to proliferate in vitro with fetal bovine serum (FBS), and cardiac
function has been preserved by coronary vein infusion of MSC in a
swine model [5]. We decided to culture BM-MSC with platelet-rich
plasma (PRP), because the platelet lysate could replace FBS [6].
Platelets are known to contain many kinds of growth factors, such
as FGF2 and PDGF, and they secrete them upon activation. PRP hassting by Elsevier B.V. All rights reserved.
Abbreviations
BM-MSC bone marrow-derived mesenchymal stem cells
PRP platelet rich plasma
FBS fetal bovine serum
FACS ﬂuorescence activated cell sorting
GFP green ﬂuorescent protein
vWF von Willbrand factor
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promote wound healing [7]. We thought it was desirable to culture
a patient's BM-MSC with his or her own PRP for safety reasons.
In this study, we examined the safety and efﬁcacy of intra-
muscular injection of cultured BM-MSC into the ischemic region.
2. Methods
2.1. Preparation of canine PRP
Ten-month-old male beagles (9.2e10.2 kg) were purchased
from Oriental Yeast Co. Ltd, Tokyo, Japan, and housed at animal
facilities in Hamry Co. Ltd, Koga, Japan. Animal studies were con-
ducted according to protocols approved by the Animal Care and Use
Committee in National Center for Global Health and Medicine and
Hamry Co. Ltd.
Preparation of canine PRP was conducted following procedures
previously described by Hamada et al. with minor modiﬁcations
[8]. Three hundred ml of heparinized canine blood was collected
from 6 beagles, because it was not possible to obtain a sufﬁcient
amount of blood from a single dog. Aliquots of 50 ml blood were
centrifuged for 10 min at 200  g at room temperature. The yellow
plasma (containing the buffy coat with platelets) was separated
from the other components and centrifuged again for 20 min at
1500  g at room temperature. The upper, platelet-poor plasma
layer was separated and discarded. The remaining PRP layer was
then divided into 500 ml aliquots and stored at 30 C until use.
Each aliquot was defrosted one hour before adding it to the
medium.
2.2. Preparation of human PRP
Preparation of human PRP followed almost the same procedures
used with canine PRP but without using pooled blood. In brief,
peripheral venous blood (200 ml) was drawn from each of three
healthy male volunteers (designated #1e3) with informed consent
and separately collected into bags (KBS-200CA8L, Kawasumi)
containing acid citrate dextrose solution formula anticoagulant.
Aliquots of 2 ml PRP were stored at 30 C until use. Each aliquot
was defrosted one hour before adding to the medium.
2.3. Culture of canine BM-MSC
Five to twelve ml of canine bonemarrowwas aspirated from the
iliac bone of each of the beagles under whole body anesthesia
(n ¼ 6). Equal volumes of PBS were added to each bone marrow
aspirate and overlaid on 10 ml of Ficoll. After centrifugation for
20 min at 500 g at PT, the buffy coat was separated. Then the cells
were washed twice with PBS and suspended in 15 ml of a-MEM
(Life Technologies) containing 20 mg/ml of gentamicin and 2IU/ml
of heparin-supplemented 10% FBS or PRP. Two out of these six bone
marrow samples were cultured with 10% FBS, and the rest were
cultured with 10% PRP on T75 ﬂasks. After the ﬁrst passage, one ofthe FBS grown MSC cultures and one of the PRP-grown MSC cul-
tures were plated on 6 well plates at a density of 3  104/well. Half
of the plates were grown in 10% FBS, and the other half were grown
in 10% PRP. Cells were observed under an IX71 microscope
(Olympus), and phase contrast images were taken with a CCD
camera (DP71, Olympus) every other day. Three of the canine MSC
cultures grown in 10% PRP were continued for 3 weeks until cell
transplantation.
2.4. Culture of human BM-MSC
Ten ml of bone marrow were aspirated from the iliac bones of
the same healthy volunteers (#1e3) using disposable Illinois bone
marrow needles (DIN1515X, CareFusion) under local anesthesia.
Bone-marrow-derived cells were isolated with the same procedure
used in the canine cases, and more than 3  107 cells were
disseminated on the T75 ﬂask in media containing 10% of their own
PRP and incubated at 37 C, 5% CO2. Media were changed 4 days
later to remove ﬂoating cells. When the cells became sub-conﬂuent
7 days later, they were detached using TrypLE Select (Life Tech-
nologies), suspended in 35ml of medium, and replated on the T175
ﬂask. Eleven days later, the cells were passaged and counted. Cells
were used for FACS analysis, endotoxin tests, mycoplasma tests, and
chromosomal analysis at P2. Some of the P2 cells were transfected
by lentivirus containing GFP cDNA to label them in order to trace
the donor cells after transplantation.
2.5. Fluorescence activated cell sorting (FACS) analysis
Cultured human BM-MSC were harvested with TrypLE Select,
and 1  106 cells were incubated with primary antibodies for
30min at 4 C. The primary antibodies used in this studywere FITC-
conjugated anti-CD105, PE-conjugated anti-CD73, FITC-conjugated
anti-CD90, FITC-conjugated anti-CD45, FITC-conjugated anti-CD34,
PE-conjugated anti-CD11b, and PE-conjugated anti-CD14, FITC-
conjugated anti-CD19 (BD Bioscience). Cells were washed with
blocking reagent and analyzed in a FACS Calibur Flow Cytometer
(Beckton Dickinson).
2.6. Karyotype analysis
Three aliquots from MSC lines of different origins (#1e3), each
containing 1  106 cells, were sent to BML Research Laboratories,
Japan, where chromosomal G-band tests were performed.
2.7. Endotoxin test
Ten ml of each culture supernatant was sent to BML Research
Laboratories, Japan, to measure the concentration of endotoxin.
2.8. Mycoplasma test
Ten ml of each culture medium containing about 1  105 cells
was sent to BML Research Laboratories, Japan, to detect Myco-
plasma DNA.
2.9. Human BM-MSC transplantation
Six-week-old NOD-SCID mice (JAPAN Clea) were used for the
transplantation experiments examining human BM-MSC. After the
left iliac artery of each SCID mouse was ligated and dissected,
claudication due to the ischemia of the limb was observed. One
million cultured cells of each human BM-MSC (#1e3) were injected
into the left quadriceps muscle of the mouse thigh immediately
after the ischemic limb model was prepared (n ¼ 3 each). Only PBS
S. Fukuda et al. / Regenerative Therapy 1 (2015) 72e7974was injected in the same sites of control mice (n ¼ 3). Two weeks
after cell injection, the mice were sacriﬁced, and histological
analysis was performed.
To distinguish the donor cells from the host cells, some of the P2
MSC were labeled with GFP. GFP cDNA was inserted into pLVSIN-
CMV Pur vector (TaKaRa); then 3 mg of the vector and 9 mg of
ViraPower Lentiviral Packaging Mix (Life Technologies) were
transfected into Lenti-X 293T cells (TaKaRa) by FuGENE6 Trans-
fection Reagent (TaKaRa) according to the manufacturer's in-
structions. Culture supernatant containing virus was added to the
medium of P2 MSC. One 106 #2 MSC were injected into ischemic
limb model mice using the same protocol described above (n ¼ 2).
These two mice were sacriﬁced 1 week and 2 weeks later, and the
left quadriceps muscle of their thighs was analyzed
immunohistochemically.
2.10. Tumor formation assay of human BM-MSC
To examine the tumorigenicity of cultured MSC, 1  107 cells of
human MSC (#1, 2) were transplanted into the left quadriceps
muscle of the thigh or subcutaneously into the abdomen of ten-
week old NOD-SCID mice (n ¼ 1, each). Three months later, the
mice were sacriﬁced, and the muscle, skin, liver, kidney, spleen and
lung were histologically examined.
2.11. Canine BM-MSC transplantation
The male beagles (n ¼ 4) fromwhom bone marrow had already
been aspirated were used for transplantation experiments. Each
left iliac artery was ligated and dissected to induce lower leg
ischemia. More than 6  106 cells of canine MSC were obtained
from the three dogs whose cells had been cultured with 10% PRP.
These cells were suspended in 1 ml PBS, labeled with DiI, and then
injected into the left quadriceps muscle of thigh at 10 sites at ali-
quots of 100 ml each (n¼ 3). Only PBS was injected in the same sites
of control animal (n¼ 1). The animal implanted with 6.0 106 cells
was sacriﬁced 6 weeks after operation, and the rest of animals were
sacriﬁced 2 weeks after operation; both groups were histologically
examined.
2.12. Histological analysis and immunostaining
Each murine or canine left quadriceps muscle of thigh was cut
into 3 pieces and ﬁxed in 20% formaldehyde (Muto PureFig. 1. Comparison of growth effects between FBS and PRP in canine BM-MSC. Canine pri
After the ﬁrst passage, MSC grown in FBSþwere plated on 6 well at a density of 3  104/well
d). BM-MSC cultured in PRP þ had proliferated faster than in FBSþ 6 days later (b, d). After t
(g, h). Similar results were obtained 8 days later (f, h). All phase contrast digital images weChemicals) overnight. These samples were embedded in parafﬁn,
and 5 mm serial sections were processed for hematoxylineeosin
staining (Muto Pure Chemicals). For immunostaining to detect
GFP, sections were incubated with Biotin-conjugated anti-GFP
antibodies (1:750; Gene Tex) overnight at 4 C. After incubation
with streptavidin-alkaline phosphatase (Vector Lab Inc), staining
was performed using fresh alkaline phosphatase substrate
(Vector Lab Inc). For detecting mouse endothelial cells, sections
were ﬁrst incubated with rabbit anti-von Willbrand factor poly-
clonal antibodies (1:300, Dako) overnight at 4 C, and then a
secondary antibody, Alexa Fluor 594-conjugated goat anti-rabbit
IgG (1:300; Life technologies), was applied for one hour at room
temperature. For detecting canine endothelial cells, FITC-
conjugated goat anti-rabbit IgG (1:300; Life Technologies) was
used as a secondary antibody. As a negative control, sections
were incubated with blocking buffer without primary antibody.
All sections were observed under a ﬂuorescence microscope,
BIOREVO (Keyence).
For evaluating angiogenesis, we compared the ratio of
occupied area of the capillary endothelial cells in the transverse
sections of the legional muscle between control group and
MSC injected group. The total area of the each muscle
section was determined and the area stained in red (vWF positive
cells) was also added up by the image analysis software. The
latter was divided by the former and then the percentage of
occupied capillary endothelial cells of each sample was
calculated.
3. Results
3.1. Comparison of cell growth between FBS and PRP in canine BM-
MSC
Between 5 and 12ml of canine bonemarrowwas aspirated from
the iliac bone of beagles under whole body anesthesia (n ¼ 6). Two
out of these six bone marrow samples were cultured with medium
containing 10% FBS (FBSþ), and the rest were culturedwith 10% PRP
(PRPþ). After the ﬁrst passage, MSC grown in FBSþwere plated on a
6 well plate at a density of 3  104/well. Then half of the 6 wells
were grown in FBSþ, and the rest were grown in PRPþ. Cells in
PRP þ had proliferated faster than those in FBSþ 6 days later
(Fig.1b, d). Next, one of theMSC samples grown in PRPþwas plated
and cultured in the same way; similar results were obtained 8 days
later (Fig. 1f, h).mary BM-MSC were cultured with media containing 10% FBS (FBSþ) or 10% PRP (PRPþ).
. Then half of the 6 wells were grown in FBSþ (a, b), and the rest were grown in PRPþ (c,
he ﬁrst passage, MSC grown in PRPþ were plated and cultured in FBSþ (e, f) or in PRPþ
re taken every other day with an Olympus IX71 microscope. Scale bar ¼ 200 mm.
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We cultured freshly isolated human BM-MSC in vitro from three
healthy male volunteers (designated #1e3), as shown in Fig. 2a. We
obtained 200 ml of each person's peripheral blood in advance to
prepare PRP as a supplement in themedia forMSC culture. Tenml of
each bone marrow was aspirated, and all of the mononuclear cells
weredisseminatedon theT75ﬂaskafter separationbyFicoll. Primary
cultured BM-MSC started to proliferate rapidly at day 4 (Fig. 2b) and
becamenearly conﬂuent at day 7 (Fig. 2c). After passage toT175ﬂask
(Fig. 2d), they continued proliferating, and the total cell counts were
#1:9.5 106, #2:1.8 107, and #3:2.0 107 at day 11 (Fig. 2f). These
cells were cryo-preserved and further used for FACS analysis, endo-
toxin tests, mycoplasma tests, and chromosomal analysis.3.3. Safety assessment of cultured human BM-MSC
Next, we determined the quality of these cultured human BM-
MSCs by examining their surface markers and by testing for chro-
mosomal abnormality and tumorigenicity. Aliquots of 1  106 cells
(#1e#3) were incubated with primary antibodies and analyzed in a
FACS Calibur ﬂow cytometer. FACS analysis of all three samples
revealed that more than 95% of the cultured cells were positive for
CD73, CD90, CD105, while the expressions of CD45, CD34, CD11b,
CD14 and CD19were all negative (Fig. 3a). These results indicate that
contamination by hematopoietic cells was negligible. Chromosomal
analysis by G-band test revealed that all three samples had normal
karyotypes (Fig. 3b). Neither endotoxin nor mycoplasma DNA was
detected any of the MSC culture media tested. To examine whether
cultured theMSChad tumorigenicity, BM-MSC(#1, 2)were expanded
in PRPþ, and aliquots 1  107 cells were transplanted into the left
quadricepsmuscle of thigh or into the subcutaneous abdomenof ten-
week-old NOD-SCID mice (n ¼ 1 each). No tumor formation was
detected in the muscle, skin, liver, kidney, spleen or lung by histo-
logical analysis three months after transplantation (data not shown).3.4. Human BM-MSC transplantation into ischemic limbmodel mice
To investigate the angiogenic effect of BM-MSC, ischemic limb
models were created in 6-week-old SCID mice. When the leftFig. 2. Cell growth of human BM-MSC in the PRP containing media. (a): Schematic proced
10% their own PRP. Representative culture images of a #2 sample are shown (bee). Media we
d), and the number of cells was counted 7 days and 11 days later (e). The total numbers of t
Olympus IX71 microscope. Scale bar ¼ 150 mm.femoral artery of each SCID mouse was ligated and dissected, no
ischemia of the limb arose, presumably due to the collateral blood
supply. However, ligation and dissection of left iliac artery caused
claudication in themice. Histological analysis revealed that necrotic
damage to the quadriceps muscle of thigh was observed one week
after this operation (data not shown).
Aliquots of 1  106 cultured human BM-MSC (#1e3) were
injected into the quadriceps muscle of the thighs of ischemic limb
model mice (n ¼ 3 each) immediately after dissection of the iliac
artery. Only PBS was injected in the same sites of control mice
(n ¼ 3). Two weeks after injection, the mice were sacriﬁced.
Histological analysis revealed the extent of muscle damage did not
differ between the control and cell injected group after two weeks
(Fig. 4a upper panels). In addition, we transfected the GFP gene
into mBM-MSC from #2 donor during cell culture to trace the
donor cells after injection. More than 50% of the cells expressed
GFP before injection (data not shown). Immunostaining by anti-
GFP antibodies revealed GFP positive cells in the quadriceps
muscle one and two weeks after injection (Fig. 4a lower panels).
Then we compared the number of capillaries by examining the
expression of von Willbrand factor (vWF), one of the surface
markers of endothelial cells. We made serial transverse sections of
the left quadriceps muscle of thigh and stained them with anti-
vWF antibodies (Fig. 4b). We took ﬂuorescent micrographs of
the entire section set and calculated the percentage of the occu-
pied area of the capillary endothelial cells. The BM-MSC (#2, 3)
injected group showed a signiﬁcantly higher percentage of occu-
pied area of capillary endothelial cells than the control group,
indicating that the MSC promoted angiogenesis in the damaged
muscle (Fig. 4c).3.5. Simulation of cell therapy in the canine ischemic limb model
In order to support a human clinical trial of this cell therapy, the
entire procedure was simulated in a canine ischemic limb model as
a preclinical study. Between 5 and 12 ml of bone marrow were
aspirated from iliac bone of beagles under whole body anesthesia
(n¼ 4) and cultured in 10% PRP prepared from pooled canine blood.
Three out of these 4 BM-MSC samples grewwell, and, after 3weeks,
the culture total cell numbers were as follows; 6.0  106, 9.0  106,ure of human primary BM-MSC culture from healthy volunteers with media containing
re changed 4 days later to remove ﬂoating cells (b). Cells were passaged 7 days later (c,
he cells from different samples (#1e3) are shown in (f). All images were taken with an
Fig. 3. FACS analysis and chromosomal analysis of human BM-MSC. (a):Aliquots of 1  106 cells were incubated with primary antibodies (CD105, CD73, CD90, CD45, CD34,
CD11b, CD14, CD19) and analyzed in a FACS Calibur ﬂow cytometer. All the samples (#1e#3) showed the same patterns; representative data from the #1 sample are shown. (b)
Chromosomal analysis judged by G-band test revealed that all the samples had normal karyotypes, 46XY. Representative results of #1 are shown.
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beagles were induced, their own cultured BM-MSC were labeled
with a ﬂuorescent dye, DiI, and injected into their left quadriceps
muscles of the thigh at 10 sites with a 100 ml aliquot at each site.
Only PBS was injected into the same sites of the control animal
(n ¼ 1). The animal administered 6.0  106 cells was sacriﬁced six
weeks after operation, and the rest of the animals were sacriﬁcedtwo weeks after operation. Histological analysis revealed DiI posi-
tive BM-MSC in the quadriceps muscle of thigh at both two and six
weeks after operation (Fig. 5). Although DiI positive cells were
present around the vWF positive cells in the damaged muscle two
weeks later (Fig. 5a, c, d), the two types did not overlap. DiI positive
cells were still found in the interstitial spaces of themuscle 6 weeks
later (Fig. 5e, g, h).
Fig. 4. Human BM-MSC transplantation into ischemic limb model mice. (a): Each 1  106 cultured human MSC (#1e3) aliquot was injected into the quadriceps muscle of thigh
of an ischemic limb model mouse (n ¼ 3 each) immediately after dissection of left iliac artery. Only PBS was injected in the same sites of control mice (n ¼ 3). Two weeks after
injection, mice were sacriﬁced. Histological analysis by Hematoxylin & eosin stain showed the extent of muscle damage was not different between control (upper left) and #3 MSC
injection (upper right). GFP positive cells were stained in red by using anti-GFP antibodies and streptavidin-alkaline phosphatase. GFP-labeled #2 MSC were detected both 1 week
(lower left) and 2 weeks (lower right) after operation. (b): For detecting mouse endothelial cells, muscle sections were incubated with rabbit anti-vWF polyclonal antibodies.
Immunohistochemistry of the quadriceps muscle of thigh stained for vWF (red) with the corresponding DAPI stain (blue). Control:PBS injection, #1: #1 derived MSC, #2: #2
derived MSC, #3: #3 derived MSC. All images were taken with a Keyence BIOREVO ﬂuorescence microscope. (c): For evaluating the angiogenesis, the ratio of the occupied area of
the capillary endothelial cells was compared based on the immunostained samples mentioned above. The total area of the each muscle section was determined and the area
stained in red (vWF positive cells) was also added up by the image analysis software. The latter was divided by the former and then the percentage of occupied capillary endothelial
cells of each sample was calculated. As a control, only PBS was injected in the same sites as human BM-MSC injected group. Results are presented as mean ± SD. Comparison
between 2 groups was made using Student's t test. *P < 0.05 vs. the control group. P values are as follows; “Cont” vs “#1“, p ¼ 0.17, “Cont” vs “#2”, p ¼ 0.001, “Cont” vs “#3”,
p ¼ 0.025.
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We demonstrated that human BM-MSC expanded well in the
media containing their own PRP and that cultured cells were ho-
mogenous populations as judged by the surface markers of MSC.
There were no chromosomal abnormalities after expansion and no
tumor formation three months after transplantation into SCID
mice.
PRP is reported to be rich in growth factors and to effectively
replace FBS [6]. In fact, we also conﬁrmed that canine MSC
cultured in PRP þ medium proliferated faster than in
FBS þ medium in vitro. Feketa et al. reported that PDGF-BB and
FGF2 were essential components for the growth-promoting effect
of human platelet lysate [9]. Proteomic analysis revealed that TGF-
b, VEGF, PDGF, FGF, and EGF were highly ranked effectors of hu-
man platelet lysate activity [10]. Grifﬁths et al. reported that MSCs
cultured ﬁrst in FBS and switched to human platelet lysate
proliferated more and demonstrated less b-galactosidase produc-
tion and smaller cell size suggesting cellular rejuvenation [11]. On
the other hand, there was another report that long-term cell
growth induced similar gene expression changes in BM-MSC after
culture media were supplemented with either FBS or humanplatelet lysate [12]. Further study will be needed to clarify the
difference between FBS and PRP.
One of the 4 canine primary BM-MSC samples did not growwell
in the PRP þ medium. One possible reason might have been that
the initial cell number was too low; the volume of that bone
marrow aspiratewas 5ml, while the other samples weremore than
10 ml. With the human samples, 10 ml of bone marrow sufﬁced for
human primary MSC culture of all three samples. It is of note that
wewere able to obtain sufﬁcient number of human BM-MSCwithin
2 weeks; minimizing culture periods will be convenient for clinical
trials. Schallmoser et al. reported the rapid large-scale expansion of
mesenchymal stem cells from human bone marrow with pooled
human platelet lysate [13]. We have to bear in mind that there
might be individual differences in terms of quality of PRP, especially
among patients with various diseases. It will be important to
measure the concentration of several growth factors in each PRP
before starting culture. Although we think it much safer to use an
individual's own PRP rather than pooled human platelet lysate for
MSC culture, pooled human platelet lysate might be useful in case
of poor growth of BM-MSC by their own PRP.
Moreover, we proved that transplanted human BM-MSC pro-
moted angiogenesis in ischemic limb model mice, because the
Fig. 5. Canine BM-MSC transplantation into ischemic limb. Left iliac artery of each male beagle (n ¼ 4) was ligated and dissected to induce lower leg ischemia. Their own BM-MSC
were cultured with 10% PRP, labeled with DiI, and then injected into the left quadriceps muscle of thigh at 10 sites with 100ml aliquots (n ¼ 3). Only PBS was injected into the same
sites of the control animal (n ¼ 1). The animal implanted with 9.0  106 cells was sacriﬁced 2 weeks after operation (aed) and the animal implanted with 6.0  106 cells was
sacriﬁced 6 weeks after operation (eeh). (b, f): H&E staining of left quadriceps muscle of thigh. (a, c, d, e, g, h):Fluorescent micrographs after immunostaining for vWF (green). DiI
(red), DAPI (blue). DiI positive transplanted cells were not overlapped with vWF positive endothelial cells. All images were taken with a Keyence BIOREVO ﬂuorescence microscope.
S. Fukuda et al. / Regenerative Therapy 1 (2015) 72e7978number of the capillaries signiﬁcantly increased in the legional
muscle. Recently Mikami et al. reported that autologous BM-MSC
implantation induced angiogenesis in a rabbit ischemic model
[14]. They also reported that only a very small number of implanted
MSC differentiated into endothelial cells. Because we were not able
to show that the implanted MSC became endothelial cells in the
muscle, there remains a possibility that implanted MSC secreted
several soluble factors that promoted angiogenesis in situ.We performed this preclinical simulation study using beagles to
prove the safetyof this therapeutic procedure.We realized that itwas
difﬁcult to prove the efﬁcacy of this cell therapy in our canine model
because the samplenumberwas too small. In addition, itwasdifﬁcult
to evaluate the number of new capillaries, because the sites and
extent of damagemuscle varied evenwhen the same iliac arterywas
completely dissected. We can only say that there were no adverse
effects, at least until 6 weeks, even if the transplanted cells survived.
S. Fukuda et al. / Regenerative Therapy 1 (2015) 72e79 795. Conclusions
Because human BM-MSC were cultured with own PRP and
safely expanded, we can expect to achieve therapeutic angiogenesis
by transplanting them.
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